No Data
No Data
Adhera Therapeutics, Now on OTCQB, Files to Offer Stock and Warrants and Seeks Nasdaq Capital Market Listing >ATRX
Adhera Therapeutics, Now on OTCQB, Files to Offer Stock and Warrants and Seeks Nasdaq Capital Market Listing >ATRX
Adhera Therapeutics Announces Appointed Zahed Subhan PhD MBA JD As CEO, Senior Management Changes, Plans For NASDAQ Uplist
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB:ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8,
Adhera Therapeutics signs letter of intent to acquire cancer therapy
Adhera Therapeutics (OTCQB:ATRX) said on Tuesday the company had entered a heads of terms agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel protein complex for tar
Adhera Therapeutics Signs Letter Of Intent To Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin >ATRX
Adhera Therapeutics Signs Letter Of Intent To Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin >ATRX
Adhera Therapeutics appoints new Chairman of the Board, focuses on uplist to Nasdaq
Adhera Therapeutics (OTCPK:ATRX +10.9%) is pleased to announce the appointment of Trond K. Waerness as Chairman of the Co.'s Board of Directors.Mr. Waerness has been serving as a Director at Adhera si
Adhera Therapeutics provides update on mid-stage MLR-1019 Parkinson’s disease trial
Adhera Therapeutics (OTCPK:ATRX +10.5%) announces that manufacturing has commenced of MLR-1019 (armesocarb), a drug licensed by the company from Melior Discovery, for use in the company's planned Pha
No Data